Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Pfizer HIV drug receives EU approval

Pfizer HIV drug receives EU approval

25th September 2007

Pfizer has announced that its HIV-drug Celsentri (maraviroc) has been approved by the European Commission as a therapy in combination with other antiretroviral agents for treatment-experienced patients with the CCR5-tropic HIV-1 virus.

This approval is based on results from the ongoing Motivate clinical trials, which show that a combination of optimised background therapy (OBT) and maraviroc provides enhanced viral load reduction compared to OBT alone.

Furthermore, the trial shows that patients administered with OBT and maraviroc saw greater increases in CD4 white cell counts compared to those receiving solely OBT.

Maraviroc is a CCR5 antagonist and the sole available orally-administered entry inhibitor.

Filippo von Schloesser, president of Italian HIV patient organisation Fondazione Nadir Onlus, commented that the approval of Celsentri offers a new treatment option for HIV patients in Europe.

“HIV is a significant health concern in Europe and infection rates are still increasing,” he said.

“Without new medicines, resistance to current treatments is one of the biggest challenges facing HIV care today.”

In August 2007, Pfizer welcomed the approval of maraviroc in the US as a major breakthrough in the treatment of HIV, reporting a “profound need” for new therapy options for HIV patients.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.